

10th August, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza, G. Block, Bandra Kurla
Complex, Bandra (East),
Mumbai - 400 051

Script Code: 500259

Script Code: LYKALABS

Sub: Submission of Press Release on Unaudited Financial Results for the First Quarter ended June 30, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir / Madam,

Pursuant to **Regulation 30** of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the **Press Release** being issued by the Company today, regarding the Unaudited Financial Results of the Company for the first quarter ended **June 30, 2026**.

The Board of Directors at its meeting held today, i.e., August 10, 2026, has inter-alia approved the said financial results.

The above information will also be made available on the website of the Company at www.lykalabs.com

We request you to kindly take the same on your record.

Thanking you,

Yours faithfully,
For **Lyka Labs Limited**

SHAILENDRA KUMAR
AGRAWAL
Digitally signed by
SHAILENDRA KUMAR
AGRAWAL
Date: 2026.08.10
12:45:31 +05'30'

Shailendra Agrawal
Company Secretary and Compliance Officer
Encl.: as above

Press Release

Lyka Labs Limited Q1 FY27 Unaudited Financials Results

Mumbai, August 10, 2026 :

Lyka Labs Limited today announced its unaudited financial results for the first quarter ended 30th June 2026 of the financial year 2026-27

Key Financials of Q1 FY27

- Stanalone Net Total Income up 42.67% at Rs. 4272.79 Lacs.
- Consolidated Net Total Income up 26.95% at Rs. 4272.79 Lacs.
- Domestic Revenue up 15.91% at Rs. 2652.11 Lacs.
- Export Revenue up 68.03 % at Rs. 1483.42 Lacs.
- Standalone EBITDA margin @ 11.84% in Q1 FY27 as against 14.16% in Q1 FY26
- Consolidated EBITDA margin @ 11.74% in Q1 FY27 as against 13.07% in Q1 FY26
- Standalone Net Profit up 159.04 % at Rs. 210.01 Lacs.
- Consolidated Net Profit up 105.44 % at Rs. 204.66 Lacs.

Standalone Q1 FY27 at a glance

(Rs. In lacs)

Particulars	Q1 FY27	Q1 FY26	Growth in %
Revenue from Operations	4230.94	2917.64	45.01
EBITDA	501.12	413.06	21.32
Other Income	41.85	77.34	-45.89
Finance Cost	100.82	85.14	18.42
Depreciation and amortisation	200.96	211.18	-4.84
Net Profit after tax	199.33	116.74	70.75

Consolidated Q1 FY27 at a glance

(Rs. In lacs)

Particulars	Q1 FY27	Q1 FY26	Growth in %
Revenue from Operations	4230.94	3302.54	28.11
EBITDA	496.57	431.73	15.02
Other Income	41.85	63.09	-33.67
Finance Cost	100.81	85.38	18.07
Depreciation and amortisation	200.96	211.18	-4.84
Net Profit after tax	194.80	135.17	44.11

Q1 FY27 Revenue Break-up

(Rs. In lacs)

Particulars	Q1 FY27	Q1 FY26	Growth in %
Domestic			
Branded Formulation	737.67	454.58	62.27
Branded Veterinary	587.35	296.90	97.83
P2P	1,327.09	1,536.69	-13.64
Total Domestic Sales	2,652.11	2,288.17	15.91
Exports			
Branded Formulation	1,483.42	882.85	68.03
Total Export Sales	1,483.42	882.85	
Other Operating Income	95.41	131.52	-27.46
Consolidated Revenue from Operations	4,230.94	3,302.54	
Other Income	41.85	63.09	-33.67
Consolidated Net Total Income	4,272.79	3,365.63	26.95

About Lyka Labs Limited:

Lyka Labs Limited is in the field of Manufacturing & Marketing of Finished Formulations for Human & Animal Healthcare, across various therapeutic segments.

SHAIENDRA
KUMAR
AGRAWAL
Digitally signed by
SHAIENDRA KUMAR
AGRAWAL
Date: 2026.08.10
12:42:29 +05'30'

Shailendra Kumar Agarwal
Company Secretary